Heron Therapeutics, Inc.
HRTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 9, 2025 | H.C. Wainwright | Brandon Folkes | $6.00(+183%) | $2.12 | TheFly |
| May 16, 2024 | Northland Securities | Carl Byrnes | $9.00(+180%) | $3.22 | StreetInsider |
| Mar 13, 2024 | Needham | Serge Belanger | $5.00(+66%) | $3.01 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | downgrade | Buy →Neutral | Aug 11, 2026 |
| Needham | downgrade | Buy →Hold | Jun 3, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 3, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 9, 2026 |
| Needham | maintain | Buy | Aug 8, 2025 |
| Needham | maintain | Buy | Apr 11, 2025 |
| Needham | maintain | Buy | Feb 28, 2025 |
| Needham | maintain | Buy | Dec 4, 2024 |
| Needham | maintain | Buy | Nov 13, 2024 |
| Needham | maintain | Buy | Sep 25, 2024 |
| Needham | maintain | Buy | Aug 7, 2024 |
| Needham | maintain | Buy | May 16, 2024 |
| Needham | maintain | Buy | May 8, 2024 |
| Needham | maintain | Buy | Apr 11, 2024 |
| Needham | maintain | Buy | Mar 13, 2024 |
| Needham | maintain | Buy | Nov 15, 2023 |
| Needham | maintain | Buy | Aug 15, 2023 |
| Needham | maintain | Buy | Jul 25, 2023 |
| Needham | maintain | Buy | May 12, 2023 |
| Needham | maintain | Buy | Apr 21, 2023 |
| Evercore ISI Group | maintain | Outperform | Mar 24, 2023 |
| Needham | maintain | Buy | Mar 24, 2023 |
| Needham | maintain | Buy | Nov 9, 2022 |
| Needham | maintain | Buy | Jun 30, 2022 |
| Needham | maintain | Buy | May 10, 2022 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 10, 2026 | $-0.03 | $-0.01 | $37.7M | $42.2M |
| May 11, 2026 | $-0.04 | $-0.03 | $34.7M | $36.7M |
| Feb 26, 2026 | $-0.02 | $-0.03 | $40.6M | $39.9M |
| Nov 4, 2025 | $-0.05 | $-0.01 | $38.2M | $39.0M |
| Aug 8, 2025 | $-0.02 | $-0.01 | $37.2M | $39.1M |
| May 6, 2025 | $0.01 | $-0.01 | $38.9M | $38.3M |
| Feb 27, 2025 | $0.02 | $-0.03 | $40.8M | $36.7M |
| Nov 12, 2024 | $-0.03 | $-0.03 | $42.3M | $37.4M |
News
CARY, N.C., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, November 9, 2026, at 8:30 a.m. ET to report third quarter financial results and discuss recent business highlights.
Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) and Heron Therapeutics (NASDAQ: HRTX - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations. Analyst Ratings This is a summary of
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
Heron Therapeutics NASDAQ: HRTX reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the comparable prior-year period, while management said sales of its key products came in below its internal expectations.